60 results
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
21 Jun 24
Automatic shelf registration
4:45pm
incorporated by reference herein, including statements regarding our future results of operations and financial position, business strategy, prospective products … herein, including statements regarding our future results of operations and financial position, business strategy, prospective products, product
S-3ASR
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Automatic shelf registration
4:05pm
, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research … by reference herein, including statements regarding our future results of operations and financial position, business strategy, prospective products
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
CRINETICS PHARMACEUTICALS | Phase 3 design strategy
Carcinoid Syndrome is a Serious Disease and Patients Need Better Treatment Options NETs … syndrome.
Strategy to Enable Paltusotine to Serve a Greater Number of Patients Acromegaly (11,000) Carcinoid Syndrome Switching from Depots (10,000
8-K
EX-10.1
qbefgglm19b wz9e2m
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-10.2
sl4r155 g7jor
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
424B5
40fr9
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
omwce42iu7gx8y
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.1
zho9u rk3wh
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
424B5
j9x8kc
12 Aug 22
Prospectus supplement for primary offering
8:31am
8-K
EX-99.1
gv8iqhpprw7 ah
25 May 22
Regulation FD Disclosure
7:02am